Volume 23, Number 6—June 2017
Research
Distribution and Quantitative Estimates of Variant Creutzfeldt-Jakob Disease Prions in Tissues of Clinical and Asymptomatic Patients
Table 1
Endpoint titration of reference sample from a patient with vCJD in tgBov mice expressing bovine prion protein*
Dilution | Transmission in tgBov mice |
|
---|---|---|
No. positive mice/no. tested | Mean ± SD, incubation, d | |
Undiluted | 6/6 | 249 ± 2 |
10−1 | 6/6 | 283 ± 15 |
10−2 | 6/6 | 316 ± 21 |
10−3 | 6/6 | 342 ± 10 |
10−4 | 6/6 | 453 ± 66 |
10−5 | 2/6 | 479, 495† |
10−6 | 1/6 | 502† |
10−7 | 0/6 | >700 |
*A 10% (wt/vol) homogenate was prepared by using frontal cortex from a clinically affected patient with vCJD. Groups of 6 tgBov mice were inoculated intracerebrally with 20 μL of serial 10-fold dilutions of this homogenate. Mice were considered positive when abnormal prion protein deposition was detected in the brain. vCJD, variant Creutzfeldt-Jakob disease.
†Dilutions at which <50% of mice were positive.